Overview

Cyclophosphamide for Nasopharyngeal Carcinoma

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). We investigated the efficacy and safety of metronomic oral cyclophosphamide as third-line treatment or beyond.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Hong Kong
Treatments:
Cyclophosphamide